PMOS in Perimenopause: What Changes and How to Manage It

What changes about PMOS in perimenopause

What gets better

• Androgens slowly decline. Ovarian testosterone production reduces gradually after the late 30s. For most women, hirsutism stabilises (does not get worse, sometimes mildly improves) and acne becomes less prominent.
• Cycle predictability briefly improves for some. The early perimenopause window (late 30s to early 40s) can produce surprisingly regular cycles for some women with previously irregular PMOS, before cycles become irregular again as menopause approaches.
• Fertility pressure resolves. Women who are not trying to conceive often experience meaningful relief from the cycle and fertility focus of earlier PMOS care.
• Some hormonal acne improves. Lower androgens help, though not for everyone.

What gets worse

• Insulin resistance often worsens. Independent of PMOS, insulin sensitivity declines around perimenopause. For women with PMOS who already have insulin resistance, the perimenopausal change compounds the existing pattern.
• Weight gain accelerates, particularly at the waist. A 2024 review in the Journal of Endocrinology found women with PCOS gain an average of 4-6 kg of central fat during the perimenopausal transition, compared to 2-3 kg in women without PCOS.
• Type 2 diabetes risk peaks. The 35-50 age window is when many women with PMOS develop overt type 2 diabetes if it has been brewing. HbA1c screening becomes more important.
• Cardiovascular risk becomes more visible. Lipid abnormalities, blood pressure, and atherosclerotic markers worsen during perimenopause. Women with PMOS have around double the lifetime cardiovascular risk; this is when much of that risk accrues.
• Sleep disruption is common. Hot flashes, night sweats, and waking at 3am are all amplified in women with PMOS due to the underlying cortisol and insulin patterns.
• Mood symptoms can intensify. Depression, anxiety, and premenstrual mood symptoms often peak in perimenopause for women with PMOS.
• Scalp hair thinning can accelerate. The combination of androgenic alopecia and post-menopausal hair density loss compounds.

The perimenopausal PMOS treatment shift

In earlier PMOS care (20s and 30s), the focus is often cycle regulation, acne, hirsutism, fertility, and weight. In perimenopausal PMOS (late 30s to mid 40s), the focus shifts toward:

1. Metabolic protection. Insulin sensitivity, blood glucose, lipids, blood pressure. The window where preventing diabetes and cardiovascular disease is most actionable.
2. Body composition over scale weight. Maintaining muscle mass matters more than dropping kg. Strength training is more important than ever.
3. Sleep quality. Sleep disruption amplifies insulin resistance and worsens mood. Becomes a primary treatment target.
4. Mental health. Depression, anxiety, and mood symptoms often peak. Screening and treatment become more important.
5. Bone health. Estrogen decline accelerates bone loss; PMOS women may have lower baseline bone density. Strength training and vitamin D become bone-protective.
6. Hormone management decisions. Hormone therapy for perimenopausal symptoms is a different decision than birth control was. Specialist input becomes more valuable.

The PMOS perimenopause 5-pillar plan

1. Diet (the foundation, unchanged)

• 30/30/40 macros. The PMOS dietary pattern still works. Protein needs slightly increase in perimenopause; aim for 1.4 to 1.6 g/kg/day to protect muscle.
• Calorie front-loading. The Jakubowicz pattern (biggest meal at breakfast) helps with the worsened evening insulin sensitivity common in perimenopause.
• 28-35g fibre per day. Bowel function, gut microbiome, cardiovascular protection all matter more now.
• Mediterranean fat profile. Cardiovascular protection becomes a primary outcome.
• Reduce alcohol. Alcohol disrupts sleep and worsens hot flashes. Most women with perimenopausal PMOS notice meaningful sleep improvement at 2-3 drinks per week or fewer.

2. Strength training and walking (the body composition lever)

• Strength training 2-3x/week. The single most important non-dietary intervention in perimenopause. Protects muscle mass, supports bone density, improves insulin sensitivity.
• Walking 8,000-10,000 steps/day. Same as earlier PMOS care, more important now.
• Less HIIT for most. Cortisol management becomes more important in perimenopause. The HIIT that worked at 28 often does not at 42.
• Yoga or pilates. Helps with balance, flexibility, and stress regulation.

3. Sleep (the underrated lever)

• Cool bedroom. 16-18°C / 60-65°F. Helps with night sweats and sleep quality.
• Magnesium glycinate 300-400mg evening. Improves sleep depth.
• Limit caffeine after 2pm. Caffeine half-life increases in perimenopause.
• Consistent sleep window. 7-9 hours, same bedtime within 30 minutes most nights.
• Address night-time waking. If you wake at 3am consistently, get fasting glucose and cortisol checked. Often a blood sugar dip in PMOS perimenopause.

4. Supplements (the support stack)

5. Medical management (specialist input)

• HbA1c every 6-12 months. Catch pre-diabetes early.
• Lipid panel and blood pressure annually. Cardiovascular risk monitoring.
• Bone density scan at 50 or earlier if risk factors. Baseline for osteoporosis prevention.
• Mental health screen. Annual at minimum during perimenopause.
• Hormone therapy discussion. Menopausal hormone therapy for vasomotor symptoms is a separate decision from PMOS management. Specialist input is valuable; many women with PMOS benefit from MHT in perimenopause for hot flashes and bone protection.
• Metformin or GLP-1 if metabolic markers warrant. Both become more commonly prescribed in perimenopausal PMOS.

What about menopausal hormone therapy (MHT) for PMOS?

MHT (sometimes called HRT) is used for vasomotor symptoms (hot flashes, night sweats) and bone protection during perimenopause and menopause. The decision to use MHT in women with PMOS is individualised. Considerations:

• Estrogen-only vs combined. Women with a uterus typically need estrogen plus progestogen to protect the endometrium (especially important in PMOS due to baseline endometrial overgrowth risk from anovulation history).
• Transdermal vs oral estrogen. Transdermal (patch, gel) has lower clot risk and is often preferred in women with metabolic risk factors (which most women with PMOS have).
• Progestogen choice. Micronised progesterone (Utrogestan, Prometrium) is often well tolerated and may be preferable to synthetic progestins for PMOS women due to neutral metabolic effects.
• Duration. Typically used for 3-7 years around menopause; long-term use is individualised based on symptom burden and risk profile.

This is a discussion to have with a gynaecologist or specialist menopause clinician, not a self-managed decision.

Does PMOS go away at menopause?

No. The condition does not resolve. What changes is the visible symptom mix. Androgen-driven symptoms (acne, hirsutism, scalp hair loss) often stabilise. Reproductive symptoms (cycles, fertility) become less relevant. Metabolic symptoms (insulin resistance, weight gain at the waist, cardiovascular risk) typically worsen.

Women with PMOS retain elevated lifetime risks of type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease into post-menopause. The metabolic management that started in their 20s and 30s remains important for the rest of life.

Frequently asked questions

Does PMOS get better in perimenopause?

Some symptoms get better, others get worse. Androgen-driven symptoms (acne, hirsutism, scalp hair loss) often stabilise or mildly improve as ovarian androgens decline. Metabolic symptoms (insulin resistance, weight gain at the waist, lipid abnormalities, blood pressure) often worsen. Sleep, mood, and hot flashes can intensify.

Does PMOS go away at menopause?

No. The condition does not resolve. Cycle and fertility issues become less relevant. Metabolic and cardiovascular risks remain elevated and often peak around perimenopause. The management focus shifts from cycle regulation toward metabolic protection.

How does PMOS change in your 40s?

Ovarian androgens slowly decline (helping some androgen-driven symptoms), while insulin resistance often worsens (driving weight gain at the waist and elevated diabetes risk). Cycles become more irregular as menopause approaches. Sleep disruption and mood symptoms often peak. Cardiovascular and metabolic monitoring becomes the priority.

Can I get pregnant with PMOS in my 40s?

Yes, but fertility declines with age regardless of PMOS. Women with PMOS may have slightly preserved ovarian reserve compared to age-matched non-PMOS women due to lower lifetime ovulations, but egg quality still declines. Pregnancy in the 40s carries higher miscarriage and gestational diabetes risk. Specialist input is recommended.

Should I take hormone therapy if I have PMOS?

Many women with PMOS benefit from menopausal hormone therapy for vasomotor symptoms and bone protection. The decision is individualised. Transdermal estrogen is often preferred over oral due to lower clot risk in women with metabolic risk factors. Micronised progesterone is often preferred over synthetic progestins. Discuss with a specialist menopause clinician.

Will PMOS weight gain stop after menopause?

Weight gain often slows or stops after menopause, but the weight gained during perimenopause is hard to lose. The metabolic adaptations of menopause (lower resting metabolic rate, increased insulin resistance) make weight loss harder, not easier, in the post-menopausal years. Prevention during perimenopause is more practical than treatment afterward.

Does PMOS increase menopause symptoms?

Some studies suggest women with PMOS have worse vasomotor symptoms (hot flashes, night sweats), more sleep disruption, and higher rates of mood symptoms in perimenopause. The underlying insulin resistance and inflammatory profile likely contribute. Management is the same as for non-PMOS women plus the PMOS-specific metabolic protection.

When does PMOS perimenopause start?

The same as the general population: typically late 30s to mid 40s, with the average age of natural menopause at 51-52. Some research suggests women with PMOS may reach menopause slightly later (by 2-4 years on average), possibly due to delayed follicle depletion from years of anovulation. This means the perimenopausal window may extend into the late 50s for some women with PMOS.

Update your PMOS plan for the perimenopausal window

What to read next

• PMOS symptoms complete list
• PMOS weight loss diet plan
• PMOS exercise plan
• Best PMOS supplements
• PCOS is now PMOS: full renaming explainer

How this article was researched

Sources include the 2023 International Evidence-based Guideline for the Assessment and Management of PCOS, the 2024 Journal of Endocrinology review on PCOS and perimenopause, the 2023 Lancet meta-analysis on PCOS and type 2 diabetes risk, the 2024 NICE guidance on menopause, and the 2024 British Menopause Society recommendations. PCOS was renamed PMOS on 12 May 2026; perimenopausal management is unchanged under both names. This article is informational and not medical advice. Decisions about hormone therapy should be made with a qualified menopause specialist. See our editorial standards.